Nothing Special   »   [go: up one dir, main page]

EA201370208A1 - Формы рифаксимина и их применение - Google Patents

Формы рифаксимина и их применение

Info

Publication number
EA201370208A1
EA201370208A1 EA201370208A EA201370208A EA201370208A1 EA 201370208 A1 EA201370208 A1 EA 201370208A1 EA 201370208 A EA201370208 A EA 201370208A EA 201370208 A EA201370208 A EA 201370208A EA 201370208 A1 EA201370208 A1 EA 201370208A1
Authority
EA
Eurasian Patent Office
Prior art keywords
rifaximine
forms
application
rifaximin
intestines
Prior art date
Application number
EA201370208A
Other languages
English (en)
Inventor
Карен С. Гасхёрст
Донлай Ян
Мелани Ро
Натан Шультхайсс
Петинка Влахова
Джеффри С. Сталтс
Трэвис Л. Хьюстон
Original Assignee
Сэликс Фармасьютиклз, Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41016698&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201370208(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Сэликс Фармасьютиклз, Лтд. filed Critical Сэликс Фармасьютиклз, Лтд.
Publication of EA201370208A1 publication Critical patent/EA201370208A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Изобретение относится к ι Форме рифаксимина, фармацевтической композиции, включающей полиморфную ι Форму рифаксимина, которая используется для лечения, предупреждения или смягчения нарушений и заболеваний, связанных с кишечником, и к способам лечения с их применением.
EA201370208A 2008-02-25 2009-02-25 Формы рифаксимина и их применение EA201370208A1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3132908P 2008-02-25 2008-02-25

Publications (1)

Publication Number Publication Date
EA201370208A1 true EA201370208A1 (ru) 2014-06-30

Family

ID=41016698

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201370208A EA201370208A1 (ru) 2008-02-25 2009-02-25 Формы рифаксимина и их применение
EA201001372A EA021176B1 (ru) 2008-02-25 2009-02-25 Полиморфная форма рифаксимина и её применение

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201001372A EA021176B1 (ru) 2008-02-25 2009-02-25 Полиморфная форма рифаксимина и её применение

Country Status (21)

Country Link
US (7) US8067429B2 (ru)
EP (1) EP2257557A4 (ru)
JP (2) JP5706693B2 (ru)
KR (1) KR101674382B1 (ru)
CN (2) CN102015725B (ru)
AU (1) AU2009219342B2 (ru)
BR (1) BRPI0908864A2 (ru)
CA (1) CA2716830C (ru)
CR (2) CR11657A (ru)
EA (2) EA201370208A1 (ru)
GE (1) GEP20135898B (ru)
IL (1) IL207730A (ru)
MA (1) MA32161B1 (ru)
ME (1) ME01032B (ru)
MX (2) MX344737B (ru)
MY (1) MY158257A (ru)
NZ (1) NZ587099A (ru)
SG (2) SG10201607926VA (ru)
UA (2) UA101829C2 (ru)
WO (1) WO2009108730A2 (ru)
ZA (2) ZA201005961B (ru)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7923553B2 (en) 2003-11-07 2011-04-12 Alfa Wassermann, S.P.A. Processes for the production of polymorphic forms of rifaximin
US7902206B2 (en) 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
US7906542B2 (en) 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
ITMI20032144A1 (it) 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
ES2522895T3 (es) 2005-03-03 2014-11-19 Alfa Wassermann S.P.A. Nuevas formas polimorfas de rifaximina, procedimientos para su producción y uso de las mismas en preparados medicinales
US8486956B2 (en) * 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
UA101829C2 (ru) 2008-02-25 2013-05-13 Саликс Фармасьютикалз, Лтд. ФОРМА η РИФАКСИМИНА И ЕЕ ПРИМЕНЕНИЕ В ТЕРАПЕВТИЧЕСКОЙ ПРАКТИКЕ
US11779571B2 (en) 2008-02-26 2023-10-10 Salix Pharmaceuticals, Inc. Methods for treating irritable bowel syndrome (IBS)
CN102245615A (zh) 2008-10-02 2011-11-16 萨利克斯药品有限公司 治疗肝性脑病的方法
US7928115B2 (en) 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
US20110035232A1 (en) * 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
US9018684B2 (en) 2009-11-23 2015-04-28 California Institute Of Technology Chemical sensing and/or measuring devices and methods
IT1397107B1 (it) * 2009-12-28 2012-12-28 Lavagna Nuovo metodo per la preparazione di antibiotici in stato amorfo e prodotti ottenuti utilizzando detto metodo.
IT1399141B1 (it) * 2010-04-02 2013-04-05 Secci Metodo per la preparazione di rifaximina in stato amorfo.
EP2401282B2 (en) † 2009-12-28 2017-01-04 Silvio Massimo Lavagna Method for the production of amorphous rifaximin
IT1398550B1 (it) * 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
MX2012013945A (es) * 2010-06-03 2013-05-06 Salix Pharmaceuticals Ltd Nuevas formas de rifaximina y usos de las mismas.
AU2015203018B2 (en) * 2010-06-03 2016-10-20 Salix Pharmaceuticals, Ltd. New forms of rifaximin and uses thereof
EP2582707A4 (en) * 2010-06-16 2014-01-08 Apotex Pharmachem Inc POLYMORPHIC FORMS OF RIFAXIMINE
PL2593463T3 (pl) * 2010-07-12 2020-11-02 Salix Pharmaceuticals, Inc. Formulacje ryfaksyminy i ich zastosowania
US8759513B2 (en) 2010-09-13 2014-06-24 Sequent Scientific Limited Polymorphic form of rifaximin and process for its preparation
IT1403847B1 (it) 2010-09-22 2013-11-08 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina e loro uso.
KR20140026379A (ko) 2011-02-11 2014-03-05 샐릭스 파마슈티컬스 리미티드 리팍시민의 형태 및 이의 용도
WO2012150561A1 (en) * 2011-05-02 2012-11-08 Ranbaxy Laboratories Limited Rifaximin dimethylformamide solvate
WO2012155981A1 (en) 2011-05-19 2012-11-22 Friulchem Spa New process for the synthesis of rifaximin and a new pseudo-crystalline form of rifaximin obtained thereby
ITMI20110890A1 (it) * 2011-05-19 2012-11-20 A M S A Anonima Materie Sint & Affini S P A Polimorfo di rifaximina e processo per la sua preparazione
ITMI20110983A1 (it) * 2011-05-30 2012-12-01 A M S A Anonima Materie Sint & Affini S P A Amorfo di rifaximina e processo per la sua preparazione
WO2013027227A1 (en) * 2011-07-20 2013-02-28 Ind-Swift Laboratories Limited Novel polymorphic form i of rifaximin
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
WO2013067394A1 (en) 2011-11-02 2013-05-10 Salix Pharmaceuticals, Ltd Methods for treating irritable bowel syndrome (ibs) and infections
JP2015509105A (ja) 2012-01-25 2015-03-26 サリックス ファーマスーティカルズ，リミテッド リファキシミン誘導体及びその使用
JP2013184902A (ja) * 2012-03-06 2013-09-19 Aska Pharmaceutical Co Ltd リファキシミン含有結晶
CA2876737A1 (en) * 2012-06-13 2013-12-19 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
ITBO20120368A1 (it) * 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
US9849090B2 (en) 2012-12-12 2017-12-26 Sun Pharmaceutical Industries Limited Pharmaceutical compositions of rifaximin
EP2971062A2 (en) 2013-03-15 2016-01-20 ALFA WASSERMANN S.p.A. Method for diagnosing vaginal infections
KR20150129691A (ko) 2013-03-15 2015-11-20 알파 와셔만 에스.피.아. 질 감염증의 치료에 사용하기 위한 리팍시민
MX2015014307A (es) 2013-04-12 2015-12-08 Alfa Wassermann Spa Administracion de farmacos antiinflamatorios no esteroidales y composiciones, metodos y sistemas relacionados.
ITMI20131307A1 (it) * 2013-08-02 2015-02-02 A M S A Anonima Materie Sint & Affini S P A Processo per la preparazione di refaximina k
CN103509038B (zh) * 2013-09-30 2016-01-20 浙江思贤制药有限公司 一种新晶型利福昔明ζ及其制备方法
ES2621557T3 (es) * 2014-03-31 2017-07-04 Euticals S.P.A. Mezcla polimórfica de rifaximina y su uso para la preparación de formulaciones sólidas
JP6693946B2 (ja) * 2014-05-04 2020-05-13 サリックス ファーマスーティカルズ，インコーポレーテッド Ｉｂｓ微生物叢及びその使用
RS59250B1 (sr) 2014-05-12 2019-10-31 Alfasigma Spa Novi solvatni kristalni oblik rifaksimina, njegova proizvodnja, kompozicije i upotreba
WO2016003536A1 (en) * 2014-06-30 2016-01-07 Salix Pharmaceuticals, Inc. Methods for retreating irritable bowel syndrome (ibs)
US9988398B2 (en) 2016-06-07 2018-06-05 Cadila Healthcare Limited Crystalline form of rifaximin and process for its preparation
KR20230023043A (ko) 2016-09-30 2023-02-16 샐릭스 파마슈티컬스 인코포레이티드 리팍시민의 고체 분산물 형태
CN106632396B (zh) * 2017-01-06 2019-01-11 成都樵枫科技发展有限公司 γ晶型利福昔明的制备方法和用途
US10143656B1 (en) 2017-08-04 2018-12-04 Braintree Laboratories, Inc. Solid oral sulfate salt formulations for cleaning a colon and methods of using same
WO2020128583A1 (en) * 2018-12-19 2020-06-25 Friulchem S.P.A. Process for the manufacture of a tablet of rifaximin and tablet of rifaximin

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1154655B (it) 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
IT1199374B (it) * 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
SK9742002A3 (en) * 2000-01-07 2003-02-04 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
US7906542B2 (en) 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
ITMI20032144A1 (it) 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US7923553B2 (en) 2003-11-07 2011-04-12 Alfa Wassermann, S.P.A. Processes for the production of polymorphic forms of rifaximin
US20080262024A1 (en) * 2003-11-07 2008-10-23 Giuseppe Claudio Viscomi Rifaximin compositions and method of use
US7902206B2 (en) 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
CA2574301C (en) 2004-07-22 2013-09-10 Cumbre Pharmaceuticals Inc. (r/s) rifamycin derivatives, their preparation and pharmaceutical compositions
US8003118B2 (en) * 2005-03-02 2011-08-23 Kodsi Robert E Use of rifaximin for the prevention of aspiration pneumonia and/or sepsis
ES2522895T3 (es) 2005-03-03 2014-11-19 Alfa Wassermann S.P.A. Nuevas formas polimorfas de rifaximina, procedimientos para su producción y uso de las mismas en preparados medicinales
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
NZ575550A (en) 2006-09-22 2011-12-22 Cipla Ltd Rifaximin
WO2008085484A2 (en) 2006-12-28 2008-07-17 Jacobus Pharmaceutical Company, Inc. Treatment of inflammatory bowel disease with enteric coated formulations comprising 5-aminosalicylic acid or 4-aminosalicylic acid
ITMI20071241A1 (it) 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
US8383151B2 (en) * 2007-07-06 2013-02-26 Lupin Limited Pharmaceutical compositions of rifaximin
US7709634B2 (en) * 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
JP2011500552A (ja) 2007-10-10 2011-01-06 ルピン・リミテッド 胃腸障害を処置するための医薬用組み合わせおよび組成物
UA101829C2 (ru) 2008-02-25 2013-05-13 Саликс Фармасьютикалз, Лтд. ФОРМА η РИФАКСИМИНА И ЕЕ ПРИМЕНЕНИЕ В ТЕРАПЕВТИЧЕСКОЙ ПРАКТИКЕ
US8486956B2 (en) 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
AU2009244190B2 (en) * 2008-05-07 2016-02-25 Salix Pharmaceuticals, Ltd. Methods of treating bowel disease by administering a bowel cleanser and an antibiotic
US20100209495A1 (en) 2008-09-17 2010-08-19 Mylan Laboratories, Inc. Granulates, process for preparing them and pharmaceutical products containing them
US8916193B2 (en) 2008-12-10 2014-12-23 Cipla Limited Rifaximin complexes
KR20190000931A (ko) 2009-10-27 2019-01-03 루핀 리미티드 리팍시민의 고형 분산물
EP2401282B2 (en) * 2009-12-28 2017-01-04 Silvio Massimo Lavagna Method for the production of amorphous rifaximin
MX2012013945A (es) 2010-06-03 2013-05-06 Salix Pharmaceuticals Ltd Nuevas formas de rifaximina y usos de las mismas.
EP2582707A4 (en) 2010-06-16 2014-01-08 Apotex Pharmachem Inc POLYMORPHIC FORMS OF RIFAXIMINE
KR20140026379A (ko) 2011-02-11 2014-03-05 샐릭스 파마슈티컬스 리미티드 리팍시민의 형태 및 이의 용도

Also Published As

Publication number Publication date
US8754098B2 (en) 2014-06-17
US9700545B2 (en) 2017-07-11
CA2716830A1 (en) 2009-09-03
US20110105550A1 (en) 2011-05-05
JP5706693B2 (ja) 2015-04-22
NZ587099A (en) 2012-08-31
US20150299199A1 (en) 2015-10-22
EA201001372A1 (ru) 2011-04-29
WO2009108730A3 (en) 2009-12-30
IL207730A0 (en) 2010-12-30
MX2010009389A (es) 2010-11-22
AU2009219342A1 (en) 2009-09-03
BRPI0908864A2 (pt) 2018-09-18
US9359357B2 (en) 2016-06-07
CN104650114A (zh) 2015-05-27
MY158257A (en) 2016-09-30
MA32161B1 (fr) 2011-03-01
ZA201308527B (en) 2014-07-30
EP2257557A2 (en) 2010-12-08
UA101829C2 (ru) 2013-05-13
WO2009108730A2 (en) 2009-09-03
ZA201005961B (en) 2018-11-28
CN102015725A (zh) 2011-04-13
CA2716830C (en) 2019-01-08
SG188931A1 (en) 2013-04-30
KR20100127797A (ko) 2010-12-06
JP2011513243A (ja) 2011-04-28
KR101674382B1 (ko) 2016-11-09
EA021176B1 (ru) 2015-04-30
IL207730A (en) 2016-04-21
ME01032B (me) 2012-10-20
GEP20135898B (en) 2013-08-12
US8067429B2 (en) 2011-11-29
CR20150401A (es) 2015-11-19
EP2257557A4 (en) 2011-06-29
CN102015725B (zh) 2014-10-22
US20120076857A1 (en) 2012-03-29
US20140011828A1 (en) 2014-01-09
AU2009219342B2 (en) 2014-10-30
US20100239664A1 (en) 2010-09-23
US9181274B2 (en) 2015-11-10
US20160317507A1 (en) 2016-11-03
UA113275C2 (xx) 2017-01-10
US20130066079A1 (en) 2013-03-14
CR11657A (es) 2010-11-22
MX344737B (es) 2017-01-05
SG10201607926VA (en) 2016-11-29
JP2015129168A (ja) 2015-07-16

Similar Documents

Publication Publication Date Title
EA201370208A1 (ru) Формы рифаксимина и их применение
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
EA201291336A1 (ru) Замещенные 5-фтор-1н-пиразолопиридины и их применение
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201100505A1 (ru) Органические соединения для применения для лечения бактериальных инфекций
EA201170349A1 (ru) Модуляторы mif
EA201170356A1 (ru) Полиморфные и аморфные формы лакозамида и аморфные композиции
EA200971141A1 (ru) Соединения, активирующие теломеразу, и способы их применения
EA201100138A1 (ru) 4-феноксиметилпиперидины в качестве модуляторов активности gpr119
EA201001639A1 (ru) Композиции и способы их получения и применения
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
EA201101686A1 (ru) Новые композиции для лечения шмт и связанных с ней расстройств
EA201071243A1 (ru) Комбинированные композиции для лечения болезни альцгеймера и родственных заболеваний зонизамидом и акампросатом
EA201290836A1 (ru) Связанные бис-арильные арилтриазолоны и их применение
EA201390711A1 (ru) Гидроксиамидные соединения пиримидина в качестве ингибиторов деацетилаз белков и способы их применения
EA201101117A1 (ru) Ингибиторы дпп-4 для лечения диабета у детей
BRPI1013705A2 (pt) compostos, composição farmacêutica, método de tratamento de doença ou condição associada com função de trap1 e usos de compostos e de composição farmacêutica
EA201301078A1 (ru) Новые терапевтические подходы в лечении смт и связанных с ней расстройств
EA200900177A1 (ru) Замещенные ациланилиды и способы их применения
EA201200977A1 (ru) Лечение синдрома ли и ли-подобного синдрома токотриенолхинонами
EA200970337A1 (ru) Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения
EA201101182A1 (ru) Новые аминоазагетероциклические карбоксамиды
EA201201374A1 (ru) Лечение атаксии-телеангиэктазии
EA201101477A1 (ru) Органические соединения и их применение
EA201071045A1 (ru) Соединения оксадиазоантрацена для лечения диабета